You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
碩世生物(688399.SH)2021年度淨利潤預增37.88%-64.72%
格隆匯 01-16 15:36

格隆匯1月16日丨碩世生物(688399.SH)公佈,預計2021年年度實現歸屬於母公司所有者的淨利潤為11.3億元至13.5億元,與上年同期(法定披露數據)相比,將增加3.10億元到5.30億元,同比增加37.88%到64.72%。

歸屬於母公司所有者的扣除非經常性損益的淨利潤為11億元至13.2億元,與上年同期(法定披露數據)相比,將增加3.19億元到5.39億元,同比增加40.76%到68.91%。

報吿期內,國內疫情雖然得到有效控制,但仍然存在散發病例和局部地區不斷反覆的情況,新冠核酸檢測試劑仍然需求旺盛,公司繼續致力於疫情防控事業,針對疫情常態化,公司已積累了應對新冠疫情新常態的高效能力,新冠核酸檢測試劑銷售大幅增長,也帶動了其他新冠相關產品銷售的大幅增長;另外,在疫情得到有效控制的情況下,公司加強了核酸提取試劑、HPV、BV等原有產品的研發、生產、銷售工作,銷售幅度也取得較大幅度的增長。上述原因促使公司2021年整體經營業績呈現較大規模增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account